Hemostatic compositions and therapeutic regimens
Inventors
Finkielsztein, Sergio • Vournakis, John N.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to treat wounds. More specifically the present invention relates to hemostatic compositions that reduce the need for, and cost of, nursing care of patients with chronic wounds by reducing the frequency of wound dressing changes.
Core Innovation
The disclosure provides methods for topical treatment of a wound in a human subject using poly-β-1→4-N-acetylglucosamine fibers. The fibers are irradiated to reduce their length such that more than 50% of the fibers are less than about 15 µm in length. For the treatment of chronic wounds, the poly-β-1→4-N-acetylglucosamine comprises at least 70% N-acetylglucosamine monosaccharides. The resulting composition is applied topically to the wound site in the subject.
The technology demonstrates that sNAG accelerates wound closure and reepithelialization while increasing cell proliferation and vascularization in diabetic-mouse studies without an observed foreign-body response. The disclosures also report increased cell migration, granulation-tissue area, and modulation of signaling and gene-expression markers, including Ets1, MAPK/ERK, VEGFR2, FAK, and VEGF. These treatment effects facilitate less frequent dressing changes and reduce overall nursing-care burden and cost.
Claims Coverage
The claims include two independent claims directed to topical treatment of wounds in a human subject using irradiated, shortened poly-β-1→4-N-acetylglucosamine fibers.
Topical treatment of a wound with irradiated, shortened fibers
The claim covers topically applying a composition comprising poly-β-1→4-N-acetylglucosamine fibers to a wound in a human subject, where irradiation reduces fiber length such that more than 50% of the fibers are less than about 15 µm in length.
Topical treatment of a chronic wound with specified monosaccharide content
The claim covers topically applying a composition comprising irradiated poly-β-1→4-N-acetylglucosamine fibers to a chronic wound in a human subject, where more than 50% of the fibers are less than about 15 µm in length and the poly-β-1→4-N-acetylglucosamine comprises at least 70% N-acetylglucosamine monosaccharides.
The independent claims cover topical treatment of human wounds and chronic wounds using irradiated poly-β-1→4-N-acetylglucosamine fibers characterized by a specified length distribution and monosaccharide content.
Stated Advantages
In diabetic-mouse studies, sNAG accelerates wound closure, wound contraction, and early reepithelialization while increasing cell proliferation and vascularization.
No foreign-body response is observed in the reported diabetic-mouse studies.
Less frequent dressing changes reduce nursing-care burden and cost.
Treated wounds exhibit increased reepithelialization length and granulation-tissue area alongside increased cell migration, cell counts, and VEGF-related signaling responses.
Documented Applications
Topical treatment of wounds in human subjects using a composition comprising poly-β-1→4-N-acetylglucosamine fibers.
Treatment of chronic wounds, including diabetic ulcers, venous stasis ulcers, arterial insufficiency ulcers, and pressure ulcers.
Wound-healing evaluations using sNAG membrane-treated and control wounds in mice.
Interested in licensing this patent?